Fig. 6: GLP-1RA/tesaglitazar effects in obese db/db mice.
From: GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
a–f, Body weight (a), cumulative food intake (b), plasma glucose (c), change in blood glucose (d) and glucose tolerance (e,f) in 6-week-old obese db/db mice treated for 4 days at a dose of 50 nmol kg−1 per day. Sample sizes for treatment with Vhcl, GLP-1RA, tesaglitazar or GLP-1RA/tesaglitazar are n = 6/7/6/7 (a,c,d) and n = 6/7/6/6 (e,f). Cumulative food intake was assessed per cage in n = 4/4/4/4 cages containing n = 6/7/6/7 mice (b). Data in a, b and e have been analysed by two-way ANOVA with Bonferroni post hoc comparison for individual time points. Data in c, d and f have been analysed by one-way ANOVA using the Bonferroni’s multiple comparison test. Data represent means ± s.e.m.; asterisks indicate *P < 0.05, **P < 0.01, ***P < 0.001. Black asterisks indicate comparison to Vhcl, red asterisks indicate comparison to GLP-1RA, blue asterisks indicate comparison to tesaglitazar. Exact P values for treatment effects are: a, P = 0.0353 (red asterisk), P = 0.0078 (black asterisks) and P = 0.0031 (blue asterisks); b, P = 0.0112 (red asterisk), P = 0.0007 (black asterisks) and P = 0.0002 (blue asterisks); c, P = 0.0062 (red asterisks) and P = 0.0025 (blue asterisks); d, P = 0.0409 (black asterisk), P = 0.0027 (red asterisks) and P = 0.0032 (blue asterisks); e, P = 0.0165 (red asterisk), P = 0.0009 (black asterisks) and P = 0.0002 (blue asterisks); f, P = 0.0075. For exact P values at individual time points (a,b,e), see the data source file.
